Inhibition of chemoresistance and enhancement of chemosensitivity

The Dresden research company RESprotect GmbH was founded in 2000 and is located close to the clinics of the University of Dresden and the Max Planck Institute of Molecular Cell Biology and Genetics. RESprotect is focused on developing new therapeutics designed to inhibit chemoresistance and enhance chemosensitivity. Main targets are cancer and infectious diseases. The drugs are used in combination with conventional therapies.

1. Cancer

More effective chemotherapy with fewer side effects:
Cancer is the second leading cause of death in Europe and North America. RESprotect is focusing on the inhibition of chemoresistance and the enhancement of chemosensitivity against cytostatic treatment. This is supposed to increase the recovery chances for patients and to reduce the side effects of chemotherapy.